EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


NanoViricides Inc (NYSE:NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients.

What Happened: NanoViricides completed the development of an oral gummies (chewable gel) formulation of NV-CoV-2 for the benefit of symptomatic non-hospitalized patients.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

The Company believes that this formulation may have advantages in drug bioavailability over oral pills because of partial sublingual absorption that avoids the gastrointestinal tract. 

NanoViricides has previously developed an injectable formulation of NV-CoV-2 that it believes may not require infusion, allowing treatment of severe cases without hospitalization.

NanoViricides has also very recently developed formulations of both NV-CoV-2 and NV-CoV-2-R for direct inhalation into lungs using a nebulizer. 

Why It Matters: NV-CoV-2 is non-immunogenic and non-allergenic.

Further, it has not caused hypersensitivity or adverse reactions at injection sites or other adverse events in multiple animal studies. 

The candidate was safe and well-tolerated in animal models at very high dosages in single and multiple-dosing studies below the maximum tolerable dose of 1,500 mg/Kg. 

The Company has previously demonstrated that NV-CoV-2 was effective in multiple cell culture studies against unrelated coronaviruses. 

Related Link: EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile.

Price Action: NNVC shares closed at $4.67 on Friday.

Image by Arek Socha from Pixabay


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: BiotechNewsPenny StocksHealth CareExclusivesGeneralCOVID-19 Coronavirus